VivaZome appoints David Haylock PhD as CEO

Dr Haylock joined the Company as Chief Scientific Officer (CSO) in July, 2019. In his role as CEO, Dr Haylock will maintain his CSO function. Previously Dr Haylock has held senior leadership and management roles iat CSIRO, the Australian Stem Cell Centre, the Peter MacCallum Cancer Centre and the Institute for Medical and Veterinary Sciences. David has a wealth of experience in stem cell biology, cellular therapies and cell manufacturing, all directly relevant to VivaZome’s exosome therapies.

Read full media release here